Hello, I'm Gareth Mitchell. Welcome to Business Daily. This week we're looking at the relationship between science and business.

Cultivated meat was on the menu yesterday, along with personalised medicine, as we began exploring synthetic biology, one of the most rapidly developing business sectors worldwide.

From the foods we eat to the medicines we buy, one expert told us that up to 60% of our future

products could be made through synthetic biology.

Today is all about opportunities and risks.

People can edit genes in their garages these days, so who's regulating this space?

And from biology as a service to bacteria as food factories, I'm exploring some exciting new business models.

What Ginko is building is you can think about it a little bit like cloud infrastructure,

like Amazon Web Services or something like that, where we have invested in the physical infrastructure

and have built the IP and the data that's required to make it easier to engineer biology.

That's all to come on today's episode of Business Daily. I'm here at the Francis Crick Institute

in London in the advanced sequencing facility, as you can hear from all the thrum of the machines around me.

And the Crick is one of the UK's leading research centres in the biosciences.

Hosting me is Dr Maria Rodriguez and she's the project manager here in the facility.

So what kind of jobs come through this advanced

sequencing facility every day then, Maria? So we are the sequencing service provider for the whole

institute. So we have samples that range from flu samples from all over the world. We sequence COVID.

We sequence cancer patients, neurological disease patients, anything that you can imagine,

anything that the researchers do here.

Can you give me a sense then of just how available, the kind of costs that may be involved

in maybe a CynBio startup that needs to sequence genomes?

So you can start by buying a small sequencer like the Oxford Nanopore Sequencer, which will

...